BioSpace News Archive

Nykode Therapeutics ASA announced it will report its financial results for the first half of 2022 on August 24, 2022 before market open and subsequently host a webcast presentation at 4 p.m. CET / 10 a.m. ET.

Hemogenyx Pharmaceuticals plc, the biopharmaceutical group developing new therapies and treatments for blood diseases, announces the appointment of Mr Stuart Tinch as Director of Quality.

Gilead Sciences, Inc. announced that the European Commission has granted Marketing Authorization for Sunlenca® injection and tablets for the treatment of HIV infection, in combination with other antiretroviral, in adults with multi-drug resistant HIV infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.

Astex Pharmaceuticals, Inc. announce that the European Medicines Agency has accepted the Marketing Authorisation Application for the oral fixed-dose combination of decitabine and cedazuridine for the initial treatment of adults with acute myeloid leukemia who are not candidates for standard induction chemotherapy.

The Medical Device Innovation Consortium formally launched its Somatic Reference Samples Initiative with a pilot project to improve the validation and regulatory review process for cancer diagnostics based on next generation sequencing.

United Imaging Healthcare, a leading global medical imaging and radiotherapy equipment company, began trading on the Science and Technology Innovation Board of the Shanghai Stock Exchange.

RELIEF THERAPEUTICS and NRx Pharmaceuticals, Inc. (NASDAQ: NRXP) (" NRx "), today announced that they have agreed to a tentative settlement of their pending litigation.

LTS LOHMANN Therapie-Systeme AG announces the closing of the acquisition of Tapemark Inc. located in St. Paul, MN, USA.

Hansa Biopharma AB today announced that the Polish Ministry of Health has agreed to include Idefirix® on its reimbursement list for desensitization of highly sensitized patients prior to kidney transplantation.

Jaguar Health, Inc. (NASDAQ:JAGX) (“Jaguar” or the “Company”) today provided Company updates and reported consolidated second-quarter 2022 financial results.